Investing.com — 周二，花旗重申了对DexCom (NASDAQ: DXCM )的买入评级和104.00美元的目标价，此举是在美国食品药品监督管理局 (FDA)公开发布警告信之后。这封最初于2025年3月4日发送的信函详细列出了去年在DexCom位于加利福尼亚州和亚利桑那州的设施检查中发现的违规行为。FDA指出，G6和G7连续血糖监测系统 ...

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures such as monitoring of acetaminophen ...

AI-enhanced glucose monitoring provides predictive analytics and personalized insights for better blood sugar management.

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...